Company Overview - AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem [4] - The company implements a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders [4] - AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion-user platform while maintaining governance standards and reporting transparency of a Nasdaq listed company [4] Leadership and Vision - Brittany Kaiser, CEO of AlphaTON Capital, is recognized for her leadership in digital rights, data sovereignty, and ethical innovation in Web3 [2] - The company aims to empower individuals through data sovereignty and responsible innovation, reflecting its mission to build a trustworthy and sustainable digital economy [3][4] - Kaiser will share insights on responsible innovation, the future of digital identity, and how tokenized ecosystems can empower individuals at the Future of Money, Governance, and the Law summit [3] Strategic Initiatives - AlphaTON Capital is engaged in network validation and staking operations, development of Telegram-based applications, and strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications [4] - The company is also advancing potentially first-in-class therapies targeting known checkpoint resistance pathways to improve patient quality of life [4]

Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technologyMIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, will present three posters to showcase the results of the ...

Core Insights - BriaCell Therapeutics Corp. and its subsidiary BriaPro are developing a novel multivalent platform called TILsRx aimed at enhancing cancer treatment through immunotherapy [1][4] - The TILsRx platform targets multiple tumor-associated and immune pathway targets to combat immune suppression and T cell exhaustion, thereby improving T cell activation and persistence in the tumor microenvironment [2][7] - The technology is expected to provide a preferred tolerability profile due to its selective targeting of cancer cells, potentially leading to improved clinical responses across various cancer types [8] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cancer care [5] - BriaPro, a pre-clinical stage company, aims to enhance the body's natural ability to fight cancer through the development of binding agents and proteins [6] Technology Details - The TILsRx platform includes multifunctional agents such as soluble CD80, anti-CD3, IL-21, and anti-STEAP1, with an early candidate target being B7-H3, which is overexpressed in several cancers [2][4] - The platform is designed to improve manufacturing efficiency by combining shared core components with specific elements targeting cell surface antigens, allowing for future flexibility in immunotherapy targets [4][5] Future Prospects - The company anticipates that the multivalent approach will be effective against multiple cancer types and may synergize with existing cell-based cancer vaccine programs [5][8] - BriaCell and BriaPro are committed to advancing the TILsRx platform through pre-clinical and clinical stages to realize its full potential in cancer treatment [4][8]

Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.The company's AI division has advanced its PredicTcell platform using expanded datasets and wet lab science to enhance predictive modeling capabilities. WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holding ...